• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva launches connected inhaler for asthma, COPD

July 13, 2020 By Nancy Crotti

Teva Pharmaceutical logo - updated

Teva (NYSE:TEVA) announced today that it has launched a Bluetooth-enabled version of its ProAir albuterol sulfate rescue inhaler.

The ProAir Digihaler’s sensors connect to a companion mobile app to provide inhaler-use information to healthcare providers. The new inhaler is available by prescription to U.S. patients age 4 and older, according to the Tel Aviv, Israel-based company.

The ProAir Digihaler is designed to detect, record and store inhaler event data, including timestamp and inhalation characteristics such as peak inspiratory flow. Patients are then able to view this data on the app, which informs them if their inhaler technique needs improvement. Patients can share these data with their healthcare providers.

The FDA approved the ProAir Digihaler in December 2018. It is part of a portfolio that includes the AirDuo Digihaler, which dispenses fluticasone propionate and salmeterol inhalation powder, and the ArmonAir Digihaler, which dispenses only fluticasone propionate. The digital AirDuo and ArmonAir inhalers are indicated for the maintenance treatment of asthma in patients 12 years of age and older. Teva said it expects to launch both of those products in the U.S. in the coming months.

“The launch of ProAir Digihaler and its companion app provides a great opportunity for bringing a new digital health tool to asthma and COPD patients in the U.S.,” said Teva Pharmaceuticals North America commercial EVP  Brendan O’Grady in a news release. “We are especially proud to provide our first Digihaler product at a time when digital health technology is growing and continues to transform patient care, since it will enable patients to electronically record and monitor their rescue inhaler use.”

“It is our belief that ProAir Digihaler and the companion app will help address an unmet need for HCPs by providing objective rescue inhaler use data when managing their patients,” added Sven Dethlefs, EVP, global marketing & portfolio at Teva Pharmaceuticals. “Ultimately, this technology may help patients who use ProAir Digihaler and its accompanying app to have a better-informed dialogue with their (healthcare provider) about their disease management and treatment decisions.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS